Pascal Dô

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 451 citations · Full text

Ifct-1501 Maps2, Immune Checkpoint Inhibitor, Pleural Disease +5

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

C. Chouaïd, C. Dujon, Pascal Dô et al. · Lung Cancer · 2014 · 187 citations

Surgical Oncology, Real-world Setting, Health Sciences +11

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

Charline Lasnon, Cédric Desmonts, Elske Quak et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 121 citations · Full text

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

S. Couraud, Pierre-Jean Souquet, Christophe Paris et al. · European Respiratory Journal · 2015 · 85 citations

Tobacco Control, Epidemiology, Tumor Microenvironment +15